2 observations: 1. big decline on heavy volume
Post# of 155052
(Total Views: 658)
Posted On: 11/29/2023 3:00:44 PM
2 observations:
1. big decline on heavy volume. likely the company is doing a raise. historically, investors have bought private shares at a discount and received warrants. they dump shares on open market to fund the purchases, ending up exchanging their public shares for private ones and getting free warrants. This would co-incide with the fact that we recently approved more shares, and likely the company needs funds right now. so, i don't see it as an indication of anything negative. could also be some tax loss selling - but likely not, as that wouldn't occur in such size in a narrow 2 day window.
2. with regard to Samsung, we all know that we've owed Samsung a lot of money for a long time - at some point, something has to give. Samsung seems to have been very patient over the years - on some level they also probably realized they made a mistake fronting that much product to a company that did not have regulatory approval to sell their drug. frankly, i'm surprised they didn't end the agreement sooner - but given how good they've been to us, i'm not surprised they've not pursued legal action (and i'm thankful for that). and let's remember - while the $30mm or so we owe them is a lot of money for us, it's not much to a company of Samsung's global scale and size - a rounding error for them, and not worth the time and effort to keep dinking around with us. again, i don't see this as a negative - just makes perfect sense if you think about it.
1. big decline on heavy volume. likely the company is doing a raise. historically, investors have bought private shares at a discount and received warrants. they dump shares on open market to fund the purchases, ending up exchanging their public shares for private ones and getting free warrants. This would co-incide with the fact that we recently approved more shares, and likely the company needs funds right now. so, i don't see it as an indication of anything negative. could also be some tax loss selling - but likely not, as that wouldn't occur in such size in a narrow 2 day window.
2. with regard to Samsung, we all know that we've owed Samsung a lot of money for a long time - at some point, something has to give. Samsung seems to have been very patient over the years - on some level they also probably realized they made a mistake fronting that much product to a company that did not have regulatory approval to sell their drug. frankly, i'm surprised they didn't end the agreement sooner - but given how good they've been to us, i'm not surprised they've not pursued legal action (and i'm thankful for that). and let's remember - while the $30mm or so we owe them is a lot of money for us, it's not much to a company of Samsung's global scale and size - a rounding error for them, and not worth the time and effort to keep dinking around with us. again, i don't see this as a negative - just makes perfect sense if you think about it.
(5)
(0)